Chemotherapy

You are here

Chemotherapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

ASCO 2018 Roundtable - Lung Cancer - Keynote 042 Trial - Keytruda (Pembrolizumab) as a Single Agent Compared to Doublet Chemotherapy for NSCLC
Drs. H. Jack West, Medical Director - Thoracic Oncology Program at Swedish Cancer Institute, President and CEO of GRACE, Karen Kelly - Associate...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemo Medication, Immunotherapies, Chemotherapy
Lung Cancer Video Library - Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC
Dr. H. Jack West, Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, President and CEO of GRACE offers updates to our Lung Cancer...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Immunotherapies
Case Based Panel Discussion - Advanced Non Squamous NSCLC, High PD-L1, No Driver Mutation - What is the Optimal 1st Line?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal 1st line treatment for a patient with advanced non squamous non small cell lung cancer, high PD-L1, and no driver mutation.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Maintenance Therapy, Adjuvant Therapy, Targeted Therapy, Immunotherapies
Case Based Panel Discussion - Advanced Non Squamous NSCLC, Low PD-L1 No Driver Mutation - Is There a Best Systemic Therapy Option?
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss if there is a best systemic therapy option for a patient with advanced non-squamous NSCLC, low PD-L1 and no driver mutation.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Maintenance Therapy, Adjuvant Therapy, Targeted Therapy, Immunotherapies
Case Based Panel Discussion - What is the Optimal Approach for a Fit Patient with Advanced Squamous NSCLC and Low Tumor PD-L1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the optimal approach for a fit patient with advanced squamous NSCLC and low tumor PD-L1 expression.
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
General Lung Cancer, Non Small Cell Lung Cancer, Chemotherapy, Immunotherapies, Adjuvant Therapy, 3rd Line and beyond, Targeted Therapy

Articles

Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time
Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
First-line treatment, Targeted Therapy, Chemotherapy, Immunotherapies
Second Line Chemotherapy Options for SCLC
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, Scans - PET-CT, etc., Symptoms
What Are Your Current Practices for Consolidation Chest Radiation for Extensive SCLC?
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy for extensive stage small cell lung cancer should lead to a change in treatment for this setting.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, Procedures & Treatments, Radiation Therapy
Should Immune Checkpoint Inhibitors and Other Therapies Be Combined Concurrently or Sequentially?
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, Molecular Testing, Targeted Therapy
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Cancer Journey:
In Treatment, Just Diagnosed
Cancer Type:
Lung Cancer
Disease Learning:
Chemotherapy, Molecular Testing, Targeted Therapy

Community Forum

Adrenal metastasis from NSCLC
Greetings all, I'm a medical doctor from Vietnam. I want to discuss to you about my patient. He is 58 years old, he is hospitalize with chronic...
Cancer Journey:
In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, Chemo Medication, Chemotherapy, First-line treatment
Local Therapies for Metastatic Lung Cancer Who, What, Why, When and How?
Hi Grace Members, Grace is happy to present in partnership with the Swedish Cancer Institute " Local Therapies for Metastatic Lung Cancer Who,...
Cancer Journey:
Just Diagnosed, In Treatment
Cancer Type:
Lung Cancer
Disease Learning:
Lung Cancer, Drugs, Targeted Therapies – ALK, Targeted Therapies - EGFR, Targeted Therapies – ROS1, Procedures & Treatments, Chemotherapy, Tumor Marker Tests, Targeted Therapy, Investigational Agents, Immunotherapies, Radiation Therapy, Non Small Cell Lung Cancer
Alternative medicine
My father has been dealing with prostate cancer for a couple of years now and is about to begin treatment. Does anybody have any information or...
Cancer Journey:
Cancer Type:
Disease Learning:
Chemotherapy